Abstract | BACKGROUND: OBJECTIVES: To assess SSTR expression and the efficacy of SSAs in mMCC, a high-grade NET. Methods In this retrospective study of 40 patients with mMCC, SSTR expression was assessed radiologically by somatostatin receptor scintigraphy (SRS; n = 39) and/or immunohistochemically when feasible (n = 9). Nineteen patients (18 had SRS uptake in MCC tumours) were treated with SSA. Disease control was defined as progression-free survival (PFS) of ≥ 120 days after initiation of SSA. RESULTS: Thirty-three of 39 patients (85%) had some degree (low 52%, moderate 23%, high 10%) of SRS uptake. Of 19 patients treated with SSA, seven had a response-evaluable target lesion; three of these seven patients (43%) experienced disease control, with a median PFS of 237 days (range 152-358). Twelve of 19 patients did not have a response-evaluable lesion due to antecedent radiation; five of these 12 (42%) experienced disease control (median PFS of 429 days, range 143-1757). The degree of SSTR expression (determined by SRS and/or immunohistochemistry) did not correlate significantly with the efficacy endpoints. CONCLUSIONS: In contrast to other high-grade NETs, mMCC tumours appear frequently to express SSTRs. SSAs can lead to clinically meaningful disease control with minimal side-effects. Targeting of SSTRs using SSA or other novel approaches should be explored further for mMCC.
|
Authors | T Akaike, J Qazi, A Anderson, F S Behnia, M M Shinohara, G Akaike, D S Hippe, H Thomas, S R Takagishi, K Lachance, S Y Park, E S Tarabadkar, J G Iyer, A Blom, U Parvathaneni, H Vesselle, P Nghiem, S Bhatia |
Journal | The British journal of dermatology
(Br J Dermatol)
Vol. 184
Issue 2
Pg. 319-327
(02 2021)
ISSN: 1365-2133 [Electronic] England |
PMID | 32320473
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2020 British Association of Dermatologists. |
Chemical References |
- Receptors, Somatostatin
- Somatostatin
|
Topics |
- Carcinoma, Merkel Cell
(drug therapy)
- Humans
- Receptors, Somatostatin
- Retrospective Studies
- Skin Neoplasms
(drug therapy)
- Somatostatin
(therapeutic use)
|